Toolkit to Examine Lifelike Language (TELL)

Buenos Aires, Argentina

Diagnostics Digital Diagnostics AI / ML Neurology

TELL enables patients and clinicians to make timely decisions about brain health through automated speech analysis, a cutting-edge, non-invasive method to identify, discriminate, and monitor neurodegenerative diseases. These disorders, including Alzheimer's and Parkinson's disease, affect 100 million people worldwide and cost over one trillion dollars annually in Latin America alone, creating an urgent need for inexpensive, flexible, and consistent markers that favor early detection. Current diagnostic tools are slow, expensive, subjective, and often inaccessible to those in non-urban areas. This leads to expensive R&D, delayed treatments, and underserved patients. TELL offers a solution with automated, affordable, and scalable speech and language tests that use artificial intelligence to capture reliable markers of brain anomalies.

✓Source: HealthTech Alpha by Galen Growth

Shareable draft

Check out Toolkit to Examine Lifelike Language (TELL) on @MedStartr Today #BrainHealth #NeurodegenerativeDiseases #NeurologicalDisorders #CognitiveHealth #Diagnostics #DigitalDiagnostics #AIML #Neurology #MedMo #MedStartrVentures

https://www.medstartr.ai/s/wG_IPlM2ywg

Get Involved in Toolkit to Examine Lifelike Language (TELL)

🏢Is this your company? Claim This Profile

Join MedStartr to verify with your work email and edit this profile

Company Info

Founded: 2022
Website: tellapp.org/

Disease Areas

Brain Health Neurodegenerative Diseases Neurological Disorders Cognitive Health

Technologies

Speech RecognitionAI/Machine LearningNLPNon-Invasive Diagnostics

🌐Website

MedStartr Engagement Score

The MedStartr Index is a reflection of how the crowds that come to MedStartr everyday to find healthcare innovations reacted. Calculated by our AI agent Fyggy based on algorithms we have been building since 2012 and over 100 different factors, the math is proprietary and complex. Suffice to say, it has been found to be highly correlative with early stage company growth. What you see here is the public version. To learn more or to get deeper access to our predictive data on startup success for your fund or company, click here.

Comments

Comments from new members are shown once the company's team has approved them. Please follow the community rules.

Be the first to comment.

What do you think of Toolkit to Examine Lifelike Language (TELL)?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Submit anonymously — my name won't be shown to the team or on this profile

Your scores and comments are shown with your review on this company's profile.